<DOC>
	<DOC>NCT01095666</DOC>
	<brief_summary>The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in Asian patients with Type 2 Diabetes who are not well controlled on metformin alone. The safety of this treatment will also be studied.</brief_summary>
	<brief_title>A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Males and females, 18 to 77 years old, with type 2 diabetes and with inadequate glycemic control Drug naive or treated with antidiabetic medication for &lt; 24 weeks Cpeptide ≥ 1.0 ng/mL Body Mass Index ≤ 45.0 kg/m² AST and/or ALT &gt; 3 times ULN Serum total bilirubin &gt; 2 mg/dL Serum creatinine ≥ 1.50 mg/dL for men or ≥ 1.40 mg/dL for women Creatine kinase ≥ 3 times ULN Symptoms of severely uncontrolled diabetes Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>